Press Releases

Press Releases

Year
News

11 February, 2020

Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer

30 January, 2020

Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

28 January, 2020

Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis

27 January, 2020

Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine

23 January, 2020

Incyte to Report Fourth Quarter and Year-End Financial Results

13 January, 2020

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

07 January, 2020

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma

02 January, 2020

Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease

Previous page of 1 2
 

For Media Inquiries

Catalina Loveman
Executive Director, Public Affairs

+1 302.498.6171 | media@incyte.com


For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Responsibility

Phone: 302.498.5914

Email: mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141

Email: layala@incyte.com

Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773

Email: cchiou@incyte.com